

| Summary Table A | | |
|---|-------------------|---------------|
| PROPOSED REGULAR BUDGET FOR THE BIENNIUM 2018-2019 | | |
| (expressed in euros) | | |
| LEVEL 2 OBJECTIVES | 2018-2019 BUDGET | % |
| 1. Describe the occurrence of cancer | 3,507,393 | 7.94 |
| 2. Understand the causes of cancer | 11,719,106 | 26.54 |
| 3. Evaluate and implement cancer prevention and control strategies | 4,317,788 | 9.78 |
| 4. Increase the capacity for cancer research | 10,950,537 | 24.80 |
| 5. Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research | 4,799,948 | 10.87 |
| 6. Enable and support the efficient conduct and coordination of research | 8,855,021 | 20.06 |
| TOTAL BUDGET | 44,149,793 | 100.00 |

| Summary Table B | | | | | | | |
|---|---|----------------------------|--------|----------------------------|--------|---|----------------------------|
| SUMMARY OF BIENNIAL RESOURCES BY LEVEL 2/3 OBJECTIVES AND SOURCES OF FUND | | | | | | | |
| (expressed in euros) | | | | | | | |
| Level 2 Level 3 | Level 2 Objectives Level 3 Objectives | Regular Budget | | | | Extra-Budgetary Resources (see note i) | |
| | | 2016-2017 Budget Amount | % | 2018-2019 Budget Amount | % | 2016-2017 Budget Amount | 2018-2019 Budget Amount |
| 1 | Describe the occurrence of cancer | | | | | | |
| 1.1 | Improve and expand reporting of descriptive cancer statistics | 1,958,877 | | 2,071,815 | | 0 | 133,103 |
| 1.2 | Support improved coverage and quality of cancer registration, particularly in low and middle-income countries (LMIC) | 848,717 | | 867,061 | | 142,000 | 234,706 |
| 1.3 | Improve tumour classification to inform cancer registration, research and treatment | 362,884 | | 568,517 | | 1,178,347 | 1,180,345 |
| | | 3,170,478 | 7.30 | 3,507,393 | 7.94 | 1,320,347 | 1,548,154 |
| 2 | Understand the causes of cancer | | | | | | |
| 2.1 | Identify the risk factors for human cancer through the conduct of epidemiological studies | 7,056,412 | | 7,054,967 | | 1,131,487 | 3,729,425 |
| 2.2 | Elucidate mechanisms of carcinogenesis through the conduct of laboratory studies | 3,575,915 | | 2,825,402 | | 162,000 | 623,636 |
| 2.3 | Provide expert evaluations of the available evidence-base to identify human carcinogens | 1,693,349 | | 1,838,737 | | 0 | 1,581,599 |
| | | 12,325,676 | 28.39 | 11,719,106 | 26.54 | 1,293,487 | 5,934,660 |
| 3 | Evaluate and implement cancer prevention and control strategies | | | | | | |
| 3.1 | Enhance understanding of interventions for cancer prevention and control | 2,639,000 | | 2,581,331 | | 398,838 | 1,000,261 |
| 3.2 | Enhance the implementation of cancer prevention and control programmes | 1,343,833 | | 1,200,232 | | 941,057 | 2,679,898 |
| 3.3 | Provide expert evaluations of the available evidence-base in order to recommend prevention strategies | 437,431 | | 536,225 | | 0 | 143,650 |
| | | 4,420,264 | 10.18 | 4,317,788 | 9.78 | 1,339,895 | 3,823,809 |
| 4 | Increase the capacity for cancer research | | | | | | |
| 4.1 | Increase human resources for cancer research | 1,632,193 | | 1,417,571 | | 827,042 | 684,401 |
| 4.2 | Develop new methodologies for cancer research | 2,880,769 | | 3,592,947 | | 195,438 | 344,740 |
| 4.3 | Provide the resources and infrastructure to support and enhance research | 5,768,385 | | 5,940,019 | | 681,414 | 356,400 |
| | | 10,281,347 | 23.68 | 10,950,537 | 24.80 | 1,703,894 | 1,385,541 |
| 5 | Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research | | | | | | |
| 5.1 | Define the vision and implement the scientific strategy of the Agency, providing the framework for the fulfilment of its objectives | 1,284,291 | | 1,358,283 | | 0 | 0 |
| 5.2 | Oversee the strategic direction of the Agency and the implementation of its programme | 392,191 | | 398,701 | | 0 | 0 |
| 5.3 | Create and maintain key strategic partnerships with national, regional and international organizations | 424,889 | | 617,675 | | 0 | 0 |
| 5.4 | Effectively communicate and disseminate the work of the Agency | 2,356,882 | | 2,425,289 | | 327,789 | 998,669 |
| | | 4,458,253 | 10.27 | 4,799,948 | 10.87 | 327,789 | 998,669 |
| 6 | Enable and support the efficient conduct and coordination of research | | | | | | |
| 6.1 | Ensure the Agency is directed and managed according to highest sector standards | 8,248,421 | | 8,396,098 | | 2,161,074 | 2,663,912 |
| 6.2 | Invest strategically towards increasing IARC's capacity | 509,160 | | 458,923 | | 90,200 | 148,376 |
| | | 8,757,581 | 20.17 | 8,855,021 | 20.06 | 2,251,274 | 2,812,288 |
| | | | | | | | |
| | TOTAL | 43,413,599 | 100.00 | 44,149,793 | 100.00 | 8,236,686 | 16,503,121 |

Notes:

i. Extra-budgetary resources include Voluntary Contributions secured at the time of budget submission, funding from the Programme Support Cost Account and the Governing Council Special Fund.

| Summary Table C | | | | | | | | | | |
|---|---|-------------------|---------------------|-------------------|-------------------|---------------------|-------------------|-------------------|---------------------|-------------------|
| SUMMARY OF REGULAR BUDGET BY LEVEL 2/3 OBJECTIVES AND YEAR | | | | | | | | | | |
| (expressed in euros) | | | | | | | | | | |
| Level 2 | Level 2 Objectives | 2018 | | | 2019 | | | 2018-2019 | | |
| Level 3 | Level 3 Objectives | Staff Budget | Non-Staff Budget | Total | Staff Budget | Non-Staff Budget | Total | Staff Budget | Non-Staff Budget | Total |
| 1 | Describe the occurrence of cancer | | | | | | | | | |
| 1.1 | Improve and expand reporting of descriptive cancer statistics | 933,571 | 90,000 | 1,023,571 | 958,244 | 90,000 | 1,048,244 | 1,891,815 | 180,000 | 2,071,815 |
| 1.2 | Support improved coverage and quality of cancer registration, particularly in low and middle-income countries (LMIC) | 333,515 | 95,000 | 428,515 | 343,546 | 95,000 | 438,546 | 677,061 | 190,000 | 867,061 |
| 1.3 | Improve tumour classification to inform cancer registration, research and treatment | 229,020 | 53,000 | 282,020 | 233,497 | 53,000 | 286,497 | 462,517 | 106,000 | 568,517 |
| | | 1,496,106 | 238,000 | 1,734,106 | 1,535,287 | 238,000 | 1,773,287 | 3,031,393 | 476,000 | 3,507,393 |
| 2 | Understand the causes of cancer | | | | | | | | | |
| 2.1 | Identify the risk factors for human cancer through the conduct of epidemiological studies | 3,023,143 | 438,600 | 3,461,743 | 3,159,024 | 434,200 | 3,593,224 | 6,182,167 | 872,800 | 7,054,967 |
| 2.2 | Elucidate mechanisms of carcinogenesis through the conduct of laboratory studies | 1,187,019 | 209,700 | 1,396,719 | 1,218,983 | 209,700 | 1,428,683 | 2,406,002 | 419,400 | 2,825,402 |
| 2.3 | Provide expert evaluations of the available evidence-base to identify human carcinogens | 790,527 | 120,000 | 910,527 | 808,210 | 120,000 | 928,210 | 1,598,737 | 240,000 | 1,838,737 |
| | | 5,000,689 | 768,300 | 5,768,989 | 5,186,217 | 763,900 | 5,950,117 | 10,186,906 | 1,532,200 | 11,719,106 |
| 3 | Evaluate and implement cancer prevention and control strategies | | | | | | | | | |
| 3.1 | Enhance understanding of interventions for cancer prevention and control | 1,067,097 | 269,500 | 1,336,597 | 1,059,234 | 185,500 | 1,244,734 | 2,126,331 | 455,000 | 2,581,331 |
| 3.2 | Enhance the implementation of cancer prevention and control programmes | 533,086 | 61,500 | 594,586 | 544,146 | 61,500 | 605,646 | 1,077,232 | 123,000 | 1,200,232 |
| 3.3 | Provide expert evaluations of the available evidence-base in order to recommend prevention strategies | 235,269 | 30,000 | 265,269 | 240,956 | 30,000 | 270,956 | 476,225 | 60,000 | 536,225 |
| | | 1,835,452 | 361,000 | 2,196,452 | 1,844,336 | 277,000 | 2,121,336 | 3,679,788 | 638,000 | 4,317,788 |
| 4 | Increase the capacity for cancer research | | | | | | | | | |
| 4.1 | Increase human resources for cancer research | 356,286 | 394,000 | 750,286 | 368,285 | 299,000 | 667,285 | 724,571 | 693,000 | 1,417,571 |
| 4.2 | Develop new methodologies for cancer research | 1,558,768 | 201,900 | 1,760,668 | 1,635,979 | 196,300 | 1,832,279 | 3,194,747 | 398,200 | 3,592,947 |
| 4.3 | Provide the resources and infrastructure to support and enhance research | 1,534,489 | 1,408,550 | 2,943,039 | 1,582,936 | 1,414,044 | 2,996,980 | 3,117,425 | 2,822,594 | 5,940,019 |
| | | 3,449,543 | 2,004,450 | 5,453,993 | 3,587,200 | 1,909,344 | 5,496,544 | 7,036,743 | 3,913,794 | 10,950,537 |
| 5 | Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research | | | | | | | | | |
| 5.1 | Define the vision and implement the scientific strategy of the Agency, providing the framework for the fulfilment of its objectives | 411,266 | 270,000 | 681,266 | 407,017 | 270,000 | 677,017 | 818,283 | 540,000 | 1,358,283 |
| 5.2 | Oversee the strategic direction of the Agency and the implementation of its programme | 87,994 | 109,500 | 197,494 | 91,707 | 109,500 | 201,207 | 179,701 | 219,000 | 398,701 |
| 5.3 | Create and maintain key strategic partnerships with national, regional and international organizations | 231,759 | 75,000 | 306,759 | 235,916 | 75,000 | 310,916 | 467,675 | 150,000 | 617,675 |
| 5.4 | Effectively communicate and disseminate the work of the Agency | 931,071 | 276,060 | 1,207,131 | 952,218 | 265,940 | 1,218,158 | 1,883,289 | 542,000 | 2,425,289 |
| | | 1,662,090 | 730,560 | 2,392,650 | 1,686,858 | 720,440 | 2,407,298 | 3,348,948 | 1,451,000 | 4,799,948 |
| 6 | Enable and support the efficient conduct and coordination of research | | | | | | | | | |
| 6.1 | Ensure the Agency is directed and managed according to highest sector standards | 3,252,667 | 886,000 | 4,138,667 | 3,352,915 | 904,516 | 4,257,431 | 6,605,582 | 1,790,516 | 8,396,098 |
| 6.2 | Invest strategically towards increasing IARC's capacity | 149,971 | 77,500 | 227,471 | 153,952 | 77,500 | 231,452 | 303,923 | 155,000 | 458,923 |
| | | 3,402,638 | 963,500 | 4,366,138 | 3,506,867 | 982,016 | 4,488,883 | 6,909,505 | 1,945,516 | 8,855,021 |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | TOTAL | 16,846,518 | 5,065,810 | 21,912,328 | 17,346,765 | 4,890,700 | 22,237,465 | 34,193,283 | 9,956,510 | 44,149,793 |

| Summary Table D | | | | | | | | | | | | | |
|---|---|---------------------------------------|--------------------|----------------|---------------------------------------|--------------------|----------------|---------------------------------------|--------------------|----------------|---------------------------------------|--------------------|----------------|
| SUMMARY OF REGULAR BUDGET FUNDED STAFF BY LEVEL 2/3 OBJECTIVES AND STAFF CATEGORY | | | | | | | | | | | | | |
| (expressed in person years) | | | | | | | | | | | | | |
| Level 2 Level 3 | Level 2 Objectives Level 3 Objectives | 2016 Staff Activity (person years) | | | 2017 Staff Activity (person years) | | | 2018 Staff Activity (person years) | | | 2019 Staff Activity (person years) | | |
| | | Professional and above | General Service | Total Staff | Professional and above | General Service | Total Staff | Professional and above | General Service | Total Staff | Professional and above | General Service | Total Staff |
| 1 | Describe the occurrence of cancer | | | | | | | | | | | | |
| 1.1 | Improve and expand reporting of descriptive cancer statistics | 3.90 | 4.70 | 8.60 | 3.90 | 4.70 | 8.60 | 3.90 | 4.70 | 8.60 | 3.90 | 4.70 | 8.60 |
| 1.2 | Support improved coverage and quality of cancer registration, particularly in low and middle-income countries (LMIC) | 1.10 | 2.30 | 3.40 | 1.10 | 2.30 | 3.40 | 1.10 | 2.30 | 3.40 | 1.10 | 2.30 | 3.40 |
| 1.3 | Improve tumour classification to inform cancer registration, research and treatment | 0.40 | 0.40 | 0.80 | 1.00 | 0.40 | 1.40 | 1.00 | 0.60 | 1.60 | 1.00 | 0.60 | 1.60 |
| | | 5.40 | 7.40 | 12.80 | 6.00 | 7.40 | 13.40 | 6.00 | 7.60 | 13.60 | 6.00 | 7.60 | 13.60 |
| 2 | Understand the causes of cancer | | | | | | | | | | | | |
| 2.1 | Identify the risk factors for human cancer through the conduct of epidemiological studies | 14.10 | 14.02 | 28.12 | 14.30 | 14.02 | 28.32 | 14.00 | 13.65 | 27.65 | 14.30 | 13.65 | 27.95 |
| 2.2 | Elucidate mechanisms of carcinogenesis through the conduct of laboratory studies | 6.55 | 8.40 | 14.95 | 6.55 | 8.40 | 14.95 | 5.30 | 6.40 | 11.70 | 5.30 | 6.40 | 11.70 |
| 2.3 | Provide expert evaluations of the available evidence-base to identify human carcinogens | 3.80 | 2.50 | 6.30 | 3.80 | 2.50 | 6.30 | 3.80 | 2.50 | 6.30 | 3.80 | 2.50 | 6.30 |
| | | 24.45 | 24.92 | 49.37 | 24.65 | 24.92 | 49.57 | 23.10 | 22.55 | 45.65 | 23.40 | 22.55 | 45.95 |
| 3 | Evaluate and implement cancer prevention and control strategies | | | | | | | | | | | | |
| 3.1 | Enhance understanding of interventions for cancer prevention and control | 6.55 | 1.90 | 8.45 | 6.55 | 1.90 | 8.45 | 6.05 | 2.60 | 8.65 | 5.55 | 2.60 | 8.15 |
| 3.2 | Enhance the implementation of cancer prevention and control programmes | 3.70 | 1.60 | 5.30 | 3.70 | 1.60 | 5.30 | 3.35 | 0.95 | 4.30 | 3.35 | 0.95 | 4.30 |
| 3.3 | Provide expert evaluations of the available evidence-base in order to recommend prevention strategies | 1.20 | 0.50 | 1.70 | 1.20 | 0.50 | 1.70 | 1.20 | 0.90 | 2.10 | 1.20 | 0.90 | 2.10 |
| | | 11.45 | 4.00 | 15.45 | 11.45 | 4.00 | 15.45 | 10.60 | 4.45 | 15.05 | 10.10 | 4.45 | 14.55 |
| 4 | Increase the capacity for cancer research | | | | | | | | | | | | |
| 4.1 | Increase human resources for cancer research | 1.00 | 3.08 | 4.08 | 1.00 | 3.00 | 4.00 | 1.00 | 3.00 | 4.00 | 1.00 | 3.00 | 4.00 |
| 4.2 | Develop new methodologies for cancer research | 6.80 | 5.48 | 12.28 | 6.00 | 5.48 | 11.48 | 7.35 | 6.40 | 13.75 | 7.55 | 6.40 | 13.95 |
| 4.3 | Provide the resources and infrastructure to support and enhance research | 4.35 | 11.20 | 15.55 | 4.95 | 11.20 | 16.15 | 4.90 | 12.10 | 17.00 | 4.90 | 12.10 | 17.00 |
| | | 12.15 | 19.76 | 31.91 | 11.95 | 19.68 | 31.63 | 13.25 | 21.50 | 34.75 | 13.45 | 21.50 | 34.95 |
| 5 | Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research | | | | | | | | | | | | |
| 5.1 | Define the vision and implement the scientific strategy of the Agency, providing the framework for the fulfilment of its objectives | 1.30 | 1.50 | 2.80 | 1.30 | 1.50 | 2.80 | 1.60 | 1.25 | 2.85 | 1.60 | 1.25 | 2.85 |
| 5.2 | Oversee the strategic direction of the Agency and the implementation of its programme | 0.00 | 1.00 | 1.00 | 0.00 | 1.00 | 1.00 | 0.00 | 1.00 | 1.00 | 0.00 | 1.00 | 1.00 |
| 5.3 | Create and maintain key strategic partnerships with national, regional and international organizations | 0.65 | 0.30 | 0.95 | 0.65 | 0.30 | 0.95 | 1.35 | 0.50 | 1.85 | 1.35 | 0.50 | 1.85 |
| 5.4 | Effectively communicate and disseminate the work of the Agency | 5.00 | 3.00 | 8.00 | 5.00 | 3.00 | 8.00 | 5.00 | 3.00 | 8.00 | 5.00 | 3.00 | 8.00 |
| | | 6.95 | 5.80 | 12.75 | 6.95 | 5.80 | 12.75 | 7.95 | 5.75 | 13.70 | 7.95 | 5.75 | 13.70 |
| 6 | Enable and support the efficient conduct and coordination of research | | | | | | | | | | | | |
| 6.1 | Ensure the Agency is directed and managed according to highest sector standards | 11.35 | 23.30 | 34.65 | 11.35 | 23.30 | 34.65 | 11.45 | 22.75 | 34.20 | 11.45 | 22.75 | 34.20 |
| 6.2 | Invest strategically towards increasing IARC's capacity | 0.75 | 0.60 | 1.35 | 0.75 | 0.60 | 1.35 | 0.65 | 0.60 | 1.25 | 0.65 | 0.60 | 1.25 |
| | | 12.10 | 23.90 | 36.00 | 12.10 | 23.90 | 36.00 | 12.10 | 23.35 | 35.45 | 12.10 | 23.35 | 35.45 |
| TOTAL | | 72.50 | 85.78 | 158.28 | 73.10 | 85.70 | 158.80 | 73.00 | 85.20 | 158.20 | 73.00 | 85.20 | 158.20 |

| Summary Table E | | | | | | | | | | | |
|--|---|------------------------|-----------------|------------------------|-----------------|-----------------------------|----------------------------|-----------------|---------------------------|----------------------------|-----------------|
| ANALYSIS OF STAFFING AND RESOURCES BY LEVEL 2/3 OBJECTIVES | | | | | | | | | | | |
| (Staff activity expressed in person years and budget expressed in euros) | | | | | | | | | | | |
| Level 2 | Level 2 Objectives | 2018 STAFF ACTIVITY | | 2019 STAFF ACTIVITY | | REGULAR BUDGETARY RESOURCES | | | EXTRA-BUDGETARY RESOURCES | | |
| | | Professional and above | General Service | Professional and above | General Service | Staff Budget 2018-2019 | Non-staff Budget 2018-2019 | Total 2018-2019 | Staff Budget 2018-2019 | Non-staff Budget 2018-2019 | Total 2018-2019 |
| Level 3 | Level 3 Objectives | | | | | | | | | | |
| 1 | Describe the occurrence of cancer | | | | | | | | | | |
| 1.1 | Improve and expand reporting of descriptive cancer statistics | 3.90 | 4.70 | 3.90 | 4.70 | 1,891,815 | 180,000 | 2,071,815 | 133,103 | - | 133,103 |
| 1.2 | Support improved coverage and quality of cancer registration, particularly in low and middle-income countries (LMIC) | 1.10 | 2.30 | 1.10 | 2.30 | 677,061 | 190,000 | 867,061 | 113,706 | 121,000 | 234,706 |
| 1.3 | Improve tumour classification to inform cancer registration, research and treatment | 1.00 | 0.60 | 1.00 | 0.60 | 462,517 | 106,000 | 568,517 | 694,345 | 486,000 | 1,180,345 |
| | | 6.00 | 7.60 | 6.00 | 7.60 | 3,031,393 | 476,000 | 3,507,393 | 941,154 | 607,000 | 1,548,154 |
| 2 | Understand the causes of cancer | | | | | | | | | | |
| 2.1 | Identify the risk factors for human cancer through the conduct of epidemiological studies | 14.00 | 13.65 | 14.30 | 13.65 | 6,182,167 | 872,800 | 7,054,967 | 622,343 | 3,107,082 | 3,729,425 |
| 2.2 | Elucidate mechanisms of carcinogenesis through the conduct of laboratory studies | 5.30 | 6.40 | 5.30 | 6.40 | 2,406,002 | 419,400 | 2,825,402 | 255,186 | 368,450 | 623,636 |
| 2.3 | Provide expert evaluations of the available evidence-base to identify human carcinogens | 3.80 | 2.50 | 3.80 | 2.50 | 1,598,737 | 240,000 | 1,838,737 | 1,232,346 | 349,253 | 1,581,599 |
| | | 23.10 | 22.55 | 23.40 | 22.55 | 10,186,906 | 1,532,200 | 11,719,106 | 2,109,875 | 3,824,785 | 5,934,660 |
| 3 | Evaluate and implement cancer prevention and control strategies | | | | | | | | | | |
| 3.1 | Enhance understanding of interventions for cancer prevention and control | 6.05 | 2.60 | 5.55 | 2.60 | 2,126,331 | 455,000 | 2,581,331 | 687,604 | 312,657 | 1,000,261 |
| 3.2 | Enhance the implementation of cancer prevention and control programmes | 3.35 | 0.95 | 3.35 | 0.95 | 1,077,232 | 123,000 | 1,200,232 | 500,898 | 2,179,000 | 2,679,898 |
| 3.3 | Provide expert evaluations of the available evidence-base in order to recommend prevention strategies | 1.20 | 0.90 | 1.20 | 0.90 | 476,225 | 60,000 | 536,225 | 81,362 | 62,288 | 143,650 |
| | | 10.60 | 4.45 | 10.10 | 4.45 | 3,679,788 | 638,000 | 4,317,788 | 1,269,864 | 2,553,945 | 3,823,809 |
| 4 | Increase the capacity for cancer research | | | | | | | | | | |
| 4.1 | Increase human resources for cancer research | 1.00 | 3.00 | 1.00 | 3.00 | 724,571 | 693,000 | 1,417,571 | - | 684,401 | 684,401 |
| 4.2 | Develop new methodologies for cancer research | 7.35 | 6.40 | 7.55 | 6.40 | 3,194,747 | 398,200 | 3,592,947 | 183,384 | 161,356 | 344,740 |
| 4.3 | Provide the resources and infrastructure to support and enhance research | 4.90 | 12.10 | 4.90 | 12.10 | 3,117,425 | 2,822,594 | 5,940,019 | 90,285 | 266,115 | 356,400 |
| | | 13.25 | 21.50 | 13.45 | 21.50 | 7,036,743 | 3,913,794 | 10,950,537 | 273,669 | 1,111,872 | 1,385,541 |
| 5 | Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research | | | | | | | | | | |
| 5.1 | Define the vision and implement the scientific strategy of the Agency, providing the framework for the fulfilment of its objectives | 1.60 | 1.25 | 1.60 | 1.25 | 818,283 | 540,000 | 1,358,283 | - | - | - |
| 5.2 | Oversee the strategic direction of the Agency and the implementation of its programme | - | 1.00 | - | 1.00 | 179,701 | 219,000 | 398,701 | - | - | - |
| 5.3 | Create and maintain key strategic partnerships with national, regional and international organizations | 1.35 | 0.50 | 1.35 | 0.50 | 467,675 | 150,000 | 617,675 | - | - | - |
| 5.4 | Effectively communicate and disseminate the work of the Agency | 5.00 | 3.00 | 5.00 | 3.00 | 1,883,289 | 542,000 | 2,425,289 | 898,669 | 100,000 | 998,669 |
| | | 7.95 | 5.75 | 7.95 | 5.75 | 3,348,948 | 1,451,000 | 4,799,948 | 898,669 | 100,000 | 998,669 |
| 6 | Enable and support the efficient conduct and coordination of research | | | | | | | | | | |
| 6.1 | Ensure the Agency is directed and managed according to highest sector standards | 11.45 | 22.75 | 11.45 | 22.75 | 6,605,582 | 1,790,516 | 8,396,098 | 1,446,786 | 1,217,126 | 2,663,912 |
| 6.2 | Invest strategically towards increasing IARC's capacity | 0.65 | 0.60 | 0.65 | 0.60 | 303,923 | 155,000 | 458,923 | 93,176 | 55,200 | 148,376 |
| | | 12.10 | 23.35 | 12.10 | 23.35 | 6,909,505 | 1,945,516 | 8,855,021 | 1,539,962 | 1,272,326 | 2,812,288 |
| | | | | | | | | | | | |
| TOTAL | | 73.00 | 85.20 | 73.00 | 85.20 | 34,193,283 | 9,956,510 | 44,149,793 | 7,033,193 | 9,469,928 | 16,503,121 |

| Summary Table F | | |
|--|-------------------|---|
| SUMMARY OF BUDGET CHANGES FROM PREVIOUS BIENNIAL BUDGET | | |
| (expressed in euros) | | |
| Description | Amount (euros) | Percentage increase/decrease from 2016-2017 |
| 1. Budget for 2016-2017 | 43,413,599 | |
| 2. Real programme increase / (decrease) | (440,957) | -1.02% |
| 3. Increase / (decrease) to unprogrammed reserve | 0 | 0.00% |
| 4. Cost increases / (decreases) due to statutory costs and inflation | 1,177,151 | 2.71% |
| 5. Budget for 2018-2019 | 44,149,793 | 1.70% |

| Summary Table G | | | | | | | | | | |
|---|------------------|------------|------------|------------------|------------|------------|--|--------------------|------------------|---------|
| SUMMARY OF REGULAR BUDGET BY COMPONENT AND CAUSE OF INCREASE/DECREASE | | | | | | | | | | |
| (expressed in euros) | | | | | | | | | | |
| COMPONENT | 2016-2017 Budget | | | 2018-2019 Budget | | | BIENNIAL INCREASE/(DECREASE) 2018-2019 vs 2016-2017 (see below note) | | | |
| | 2016 | 2017 | 2016-2017 | 2018 | 2019 | 2018-2019 | Programme | Cost | Total | % |
| Staff Budget: | | | | | | | | | | |
| Professional | 9,973,518 | 10,466,151 | 20,439,669 | 10,687,269 | 10,922,991 | 21,610,260 | 192,156 | 978,435 | 1,170,591 | 5.73% |
| General Service | 6,094,986 | 6,310,654 | 12,405,640 | 6,159,249 | 6,423,774 | 12,583,023 | (21,333) | 198,716 | 177,383 | 1.43% |
| Total Staff Costs | 16,068,504 | 16,776,805 | 32,845,309 | 16,846,518 | 17,346,765 | 34,193,283 | 170,823 | 1,177,151 | 1,347,974 | 4.10% |
| Non-Staff Budget: | | | | | | | | | | |
| Temporary assistance | 40,000 | 40,000 | 80,000 | 40,000 | 59,000 | 99,000 | 19,000 | 0 | 19,000 | 23.75% |
| Temporary advisors (experts, not coming for meetings) | 128,835 | 128,835 | 257,670 | 99,300 | 99,300 | 198,600 | (59,070) | 0 | (59,070) | -22.92% |
| Other contractual arrangements (APWs, SSAs and consultants) | 196,800 | 196,800 | 393,600 | 181,700 | 169,700 | 351,400 | (42,200) | 0 | (42,200) | -10.72% |
| Meetings (temporary advisors and participants) | 236,500 | 306,500 | 543,000 | 253,000 | 315,000 | 568,000 | 25,000 | 0 | 25,000 | 4.60% |
| Duty travel (all categories of staff including fellows) | 459,570 | 459,571 | 919,141 | 455,300 | 452,300 | 907,600 | (11,541) | 0 | (11,541) | -1.26% |
| Collaborative research agreements | 387,534 | 374,665 | 762,199 | 323,400 | 248,400 | 571,800 | (190,399) | 0 | (190,399) | -24.98% |
| Supplies | 150,396 | 150,636 | 301,032 | 128,650 | 128,890 | 257,540 | (43,492) | 0 | (43,492) | -14.45% |
| Equipment and furniture | 156,853 | 145,853 | 302,706 | 167,960 | 147,990 | 315,950 | 13,244 | 0 | 13,244 | 4.38% |
| Fellowships | 734,500 | 734,500 | 1,469,000 | 715,900 | 553,900 | 1,269,800 | (199,200) | 0 | (199,200) | -13.56% |
| Office services | 152,100 | 152,620 | 304,720 | 144,300 | 144,970 | 289,270 | (15,450) | 0 | (15,450) | -5.07% |
| Publications (including printing) | 110,050 | 110,290 | 220,340 | 176,700 | 164,900 | 341,600 | 121,260 | 0 | 121,260 | 55.03% |
| Library books & periodicals | 162,200 | 172,204 | 334,404 | 143,000 | 153,500 | 296,500 | (37,904) | 0 | (37,904) | -11.33% |
| Laboratory maintenance and supplies | 341,150 | 341,150 | 682,300 | 297,450 | 297,450 | 594,900 | (87,400) | 0 | (87,400) | -12.81% |
| IT maintenance and licences | 35,000 | 35,000 | 70,000 | 33,350 | 34,800 | 68,150 | (1,850) | 0 | (1,850) | -2.64% |
| Building services | 1,595,371 | 1,570,007 | 3,165,378 | 1,570,000 | 1,593,000 | 3,163,000 | (2,378) | 0 | (2,378) | -0.08% |
| Staff Development & Training | 95,000 | 95,000 | 190,000 | 88,000 | 79,800 | 167,800 | (22,200) | 0 | (22,200) | -11.68% |
| Director's Development Provision | 220,000 | 180,000 | 400,000 | 170,000 | 170,000 | 340,000 | (60,000) | 0 | (60,000) | -15.00% |
| Others | 86,400 | 86,400 | 172,800 | 77,800 | 77,800 | 155,600 | (17,200) | 0 | (17,200) | -9.95% |
| Total Non-Staff Costs | 5,288,259 | 5,280,031 | 10,568,290 | 5,065,810 | 4,890,700 | 9,956,510 | (611,780) | 0 | (611,780) | -5.79% |
| Unprogrammed reserve | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00% |
| TOTAL REGULAR BUDGET | 21,356,763 | 22,056,836 | 43,413,599 | 21,912,328 | 22,237,465 | 44,149,793 | (440,957) -1.02% | 1,177,151 2.71% | 736,194 1.70% | 1.70% |

Note: Causes of budget changes are classified into two groups i.e. due to programmatic requirements ('Programme') and due to cost changes ('Cost').

| Summary Table H | | | | | | | | |
|---|------------|------------|------------|---------|------------|------------|------------|---------|
| SUMMARY OF REGULAR BUDGET AND PROPOSED FINANCING | | | | | | | | |
| (expressed in euros) | | | | | | | | |
| LEVEL 2 OBJECTIVES | 2016 | 2017 | 2016-2017 | % | 2018 | 2019 | 2018-2019 | % |
| 1. Describe the occurrence of cancer | 1,518,695 | 1,651,783 | 3,170,478 | 7.30% | 1,734,106 | 1,773,287 | 3,507,393 | 7.94% |
| 2. Understand the causes of cancer | 6,045,378 | 6,280,298 | 12,325,676 | 28.39% | 5,768,989 | 5,950,117 | 11,719,106 | 26.54% |
| 3. Evaluate and implement cancer prevention and control strategies | 2,178,446 | 2,241,818 | 4,420,264 | 10.18% | 2,196,452 | 2,121,336 | 4,317,788 | 9.78% |
| 4. Increase the capacity for cancer research | 5,093,809 | 5,187,538 | 10,281,347 | 23.68% | 5,453,993 | 5,496,544 | 10,950,537 | 24.80% |
| 5. Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research | 2,205,074 | 2,253,179 | 4,458,253 | 10.27% | 2,392,650 | 2,407,298 | 4,799,948 | 10.87% |
| 6. Enable and support the efficient conduct and coordination of research | 4,315,361 | 4,442,220 | 8,757,581 | 20.17% | 4,366,138 | 4,488,883 | 8,855,021 | 20.06% |
| Total Regular Budget | 21,356,763 | 22,056,836 | 43,413,599 | 100.00% | 21,912,328 | 22,237,465 | 44,149,793 | 100.00% |
| PROPOSED FINANCING: (see Summary Table I) | | | | | | | | |
| Governing Council Special Fund | 250,000 | 250,000 | 500,000 | 1.15% | 0 | 0 | 0 | 0.00% |
| Participating States Assessments | 21,106,763 | 21,806,836 | 42,913,599 | 98.85% | 21,912,328 | 22,237,465 | 44,149,793 | 100.00% |

| Summary Table I | | | | | | | | | | | |
|---|---|--|---|-------------------|--|---|-------------------|--------------------|--------------------|----------------------------------|----------------------------|
| SUMMARY OF PROPOSED FINANCING FROM ASSESSMENTS ON PARTICIPATING STATES AND GOVERNING COUNCIL SPECIAL FUND | | | | | | | | | | | |
| (expressed in euros) | | | | | | | | | | | |
| Participating States | Number of units assigned (see Note 1 & 2) | YEAR 2018 | | | YEAR 2019 | | | BIENNIUM 2018-2019 | BIENNIUM 2016-2017 | 2018-2019 2016-2017 | 2018-2019 2016-2017 |
| | | 70% of the assessed budget borne equally | 30% of the assessed budget in accordance with the unit system | TOTAL | 70% of the assessed budget borne equally | 30% of the assessed budget in accordance with the unit system | TOTAL | TOTAL | TOTAL | % increase/decrease (see Note 3) | Amount increase/(decrease) |
| Australia | 2 | 613,545 | 257,792 | 871,337 | 622,649 | 261,618 | 884,267 | 1,755,604 | 1,737,461 | 1.04 | 18,143 |
| Austria | 1 | 613,545 | 128,896 | 742,441 | 622,649 | 130,808 | 753,457 | 1,495,898 | 1,494,554 | 0.09 | 1,344 |
| Belgium | 1 | 613,545 | 128,896 | 742,441 | 622,649 | 130,808 | 753,457 | 1,495,898 | 1,494,554 | 0.09 | 1,344 |
| Brazil | 2 | 613,545 | 257,792 | 871,337 | 622,649 | 261,618 | 884,267 | 1,755,604 | 1,737,461 | 1.04 | 18,143 |
| Canada | 2 | 613,545 | 257,792 | 871,337 | 622,649 | 261,618 | 884,267 | 1,755,604 | 1,737,461 | 1.04 | 18,143 |
| Denmark | 1 | 613,545 | 128,896 | 742,441 | 622,649 | 130,808 | 753,457 | 1,495,898 | 1,494,554 | 0.09 | 1,344 |
| Finland | 0 | 613,545 | 0 | 613,545 | 622,649 | 0 | 622,649 | 1,236,194 | 1,494,554 | -17.29 | (258,360) |
| France | 4 | 613,545 | 515,587 | 1,129,132 | 622,649 | 523,234 | 1,145,883 | 2,275,015 | 2,223,275 | 2.33 | 51,740 |
| Germany | 4 | 613,545 | 515,587 | 1,129,132 | 622,649 | 523,234 | 1,145,883 | 2,275,015 | 2,223,275 | 2.33 | 51,740 |
| India | 1 | 613,545 | 128,896 | 742,441 | 622,649 | 130,808 | 753,457 | 1,495,898 | 1,494,554 | 0.09 | 1,344 |
| Ireland | 0 | 613,545 | 0 | 613,545 | 622,649 | 0 | 622,649 | 1,236,194 | 1,251,647 | -1.23 | (15,453) |
| Italy | 2 | 613,545 | 257,792 | 871,337 | 622,649 | 261,618 | 884,267 | 1,755,604 | 2,223,275 | -21.04 | (467,671) |
| Japan | 8 | 613,545 | 1,031,167 | 1,644,712 | 622,649 | 1,046,470 | 1,669,119 | 3,313,831 | 3,194,903 | 3.72 | 118,928 |
| Morocco | 0 | 613,545 | 0 | 613,545 | 622,649 | 0 | 622,649 | 1,236,194 | 0 | 0.00 | 1,236,194 |
| Netherlands | 1 | 613,545 | 128,896 | 742,441 | 622,649 | 130,808 | 753,457 | 1,495,898 | 1,494,554 | 0.09 | 1,344 |
| Norway | 1 | 613,545 | 128,896 | 742,441 | 622,649 | 130,808 | 753,457 | 1,495,898 | 1,494,554 | 0.09 | 1,344 |
| Qatar | 0 | 613,545 | 0 | 613,545 | 622,649 | 0 | 622,649 | 1,236,194 | 1,251,647 | -1.23 | (15,453) |
| Republic of Korea | 2 | 613,545 | 257,792 | 871,337 | 622,649 | 261,618 | 884,267 | 1,755,604 | 1,494,554 | 17.47 | 261,050 |
| Russian Federation | 2 | 613,545 | 257,792 | 871,337 | 622,649 | 261,618 | 884,267 | 1,755,604 | 1,737,461 | 1.04 | 18,143 |
| Spain | 2 | 613,545 | 257,792 | 871,337 | 622,649 | 261,618 | 884,267 | 1,755,604 | 1,737,461 | 1.04 | 18,143 |
| Sweden | 1 | 613,545 | 128,896 | 742,441 | 622,649 | 130,808 | 753,457 | 1,495,898 | 1,494,554 | 0.09 | 1,344 |
| Switzerland | 1 | 613,545 | 128,896 | 742,441 | 622,649 | 130,808 | 753,457 | 1,495,898 | 1,494,554 | 0.09 | 1,344 |
| Turkey | 1 | 613,545 | 128,896 | 742,441 | 622,649 | 130,808 | 753,457 | 1,495,898 | 1,494,554 | 0.09 | 1,344 |
| United Kingdom | 4 | 613,545 | 515,587 | 1,129,132 | 622,649 | 523,234 | 1,145,883 | 2,275,015 | 2,223,275 | 2.33 | 51,740 |
| United States of America | 8 | 613,545 | 1,031,167 | 1,644,712 | 622,649 | 1,046,470 | 1,669,119 | 3,313,831 | 3,194,903 | 3.72 | 118,928 |
| TOTAL PARTICIPATING STATES | 51 | 15,338,625 | 6,573,703 | 21,912,328 | 15,566,225 | 6,671,240 | 22,237,465 | 44,149,793 | 42,913,599 | 2.88 | 1,236,194 |
| TOTAL GCSF | | | | 0 | | | 0 | 0 | 500,000 | -100.00 | (500,000) |
| TOTAL FUNDING | | 15,338,625 | 6,573,703 | 21,912,328 | 15,566,225 | 6,671,240 | 22,237,465 | 44,149,793 | 43,413,599 | 1.70 | 736,194 |

Notes:

1. The method of assessment of contributions of Participating States is detailed in Resolutions GC/15/R9, GC/54/R18, and GC/56/R6.
2. Group classification of countries for the purpose of assigning units in accordance with the applicable GC resolutions is based on the revised scale of assessments for WHO starting 2017 as adopted by the World Health Assembly in May 2016 (WHA69.14).
3. Morocco's contribution is included in the 2.88% increases in the overall assessment on Participating States for 2018-2019. Overall assessment of remaining 24 Participating States is at the same level as 2016-2017 budget. Morocco's contribution absorbs an absence of the Governing Council Special Fund (GCSF).

| Information Table A | | | | | | | | | | | | | |
|---|---------------|--------------|------------------|--------------------|----------------------|--------------|------------------|--------------------|----------------------|--------------|------------------|--------------------|----------------------|
| TOTAL STAFF AND NON-STAFF BUDGET BY SECTION AND GROUP | | | | | | | | | | | | | |
| (expressed in euros) | | | | | | | | | | | | | |
| Section | Group | 2018 | | | | 2019 | | | | 2018-2019 | | | |
| | | Staff Budget | Non-staff Budget | Group Total Budget | Section Total Budget | Staff Budget | Non-staff Budget | Group Total Budget | Section Total Budget | Staff Budget | Non-staff Budget | Group Total Budget | Section Total Budget |
| Scientific Programme (Objective 1-5) | | | | | | | | | | | | | |
| CSU | CSU | 1,267,086 | 185,000 | 1,452,086 | 1,452,086 | 1,301,790 | 185,000 | 1,486,790 | 1,486,790 | 2,568,876 | 370,000 | 2,938,876 | 2,938,876 |
| DIR | DIR | 659,391 | 515,000 | 1,174,391 | 1,174,391 | 659,445 | 515,000 | 1,174,445 | 1,174,445 | 1,318,836 | 1,030,000 | 2,348,836 | 2,348,836 |
| DIR Others | COM | 998,383 | 276,060 | 1,274,443 | 3,089,964 | 1,022,466 | 265,940 | 1,288,406 | 2,837,828 | 2,020,849 | 542,000 | 2,562,849 | 5,927,792 |
| | ETR | 356,286 | 394,000 | 750,286 | | 368,285 | 299,000 | 667,285 | | 724,571 | 693,000 | 1,417,571 | |
| | GHS | 124,484 | 120,000 | 244,484 | | 40,000 | 40,000 | 80,000 | | 124,484 | 160,000 | 284,484 | |
| | LSB | 613,751 | 207,000 | 820,751 | | 635,137 | 207,000 | 842,137 | | 1,248,888 | 414,000 | 1,662,888 | |
| EDP | PRI | 692,711 | 90,000 | 782,711 | 1,322,559 | 706,027 | 90,000 | 796,027 | 1,345,934 | 1,398,738 | 180,000 | 1,578,738 | 2,668,493 |
| | SCR | 449,848 | 90,000 | 539,848 | | 459,907 | 90,000 | 549,907 | | 909,755 | 180,000 | 1,089,755 | |
| ENV | ENV | 1,088,794 | 180,000 | 1,268,794 | 1,268,794 | 1,115,385 | 180,000 | 1,295,385 | 1,295,385 | 2,204,179 | 360,000 | 2,564,179 | 2,564,179 |
| GEN | GCS | 907,287 | 108,000 | 1,015,287 | 1,800,955 | 931,230 | 108,000 | 1,039,230 | 1,841,889 | 1,838,517 | 216,000 | 2,054,517 | 3,642,844 |
| | GEP | 678,668 | 107,000 | 785,668 | | 695,659 | 107,000 | 802,659 | | 1,374,327 | 214,000 | 1,588,327 | |
| IMO | IMO | 1,187,504 | 203,000 | 1,390,504 | 1,390,504 | 1,212,415 | 203,000 | 1,415,415 | 1,415,415 | 2,399,919 | 406,000 | 2,805,919 | 2,805,919 |
| INF | ICB | 604,152 | 95,000 | 699,152 | 1,476,122 | 619,864 | 95,000 | 714,864 | 1,700,507 | 1,224,016 | 190,000 | 1,414,016 | 3,176,629 |
| | ICE | 681,970 | 95,000 | 776,970 | | 890,643 | 95,000 | 985,643 | | 1,572,613 | 190,000 | 1,762,613 | |
| MCA | EGE | 576,422 | 95,000 | 671,422 | 1,353,047 | 593,456 | 95,000 | 688,456 | 1,385,160 | 1,169,878 | 190,000 | 1,359,878 | 2,738,207 |
| | MMB | 586,625 | 95,000 | 681,625 | | 601,704 | 95,000 | 696,704 | | 1,188,329 | 190,000 | 1,378,329 | |
| NME | BMA | 696,287 | 61,000 | 757,287 | 1,821,522 | 716,115 | 61,000 | 777,115 | 1,849,722 | 1,412,402 | 122,000 | 1,534,402 | 3,671,244 |
| | NEP | 555,749 | 75,000 | 630,749 | | 566,564 | 61,000 | 627,564 | | 1,122,313 | 136,000 | 1,258,313 | |
| | NMB | 372,486 | 61,000 | 433,486 | | 384,043 | 61,000 | 445,043 | | 756,529 | 122,000 | 878,529 | |
| SSR | ASO/ITS | 258,002 | 940,750 | 1,198,752 | 1,198,752 | 268,055 | 966,244 | 1,234,299 | 1,234,299 | 526,057 | 1,906,994 | 2,433,051 | 2,433,051 |
| SSR | DAF (GCG/SCI) | 87,994 | 109,500 | 197,494 | 197,494 | 91,707 | 109,500 | 201,207 | 201,207 | 179,701 | 219,000 | 398,701 | 398,701 |
| Administrative Programme (Objective 6) | | | | | | | | | | | | | |
| SSR | ASO | 984,432 | 779,500 | 1,763,932 | 4,366,138 | 1,022,578 | 778,016 | 1,800,594 | 4,468,884 | 2,007,011 | 1,557,516 | 3,564,527 | 8,835,022 |
| | BFO | 1,136,181 | 29,000 | 1,165,181 | | 1,167,873 | 29,000 | 1,196,873 | | 2,304,054 | 58,000 | 2,362,054 | |
| | DAF | 402,493 | 10,500 | 412,993 | | 411,258 | 10,500 | 421,758 | | 813,751 | 21,000 | 834,751 | |
| | HRO | 473,623 | 81,500 | 555,123 | | 490,082 | 81,500 | 571,582 | | 963,705 | 163,000 | 1,126,705 | |
| | ITS | 405,909 | 63,000 | 468,909 | | 415,076 | 63,000 | 478,076 | | 820,985 | 126,000 | 946,985 | |
| TOTAL | | 16,846,518 | 5,065,810 | 21,912,328 | 21,912,328 | 17,346,765 | 4,890,700 | 22,237,465 | 22,237,465 | 34,193,283 | 9,956,510 | 44,149,793 | 44,149,793 |

| Information Table B | | | | | | | | | | | |
|---|-------|-----------|---|-----------|-------|---|-------|-----------|-------|-----------|-------|
| UNITED NATIONS ACCOUNTING RATES OF EXCHANGE: EUROS TO US DOLLARS | | | | | | | | | | | |
| From January 2006 to December 2016 | | | | | | | | | | | |
| | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 |
| January | 0.845 | 0.760 | 0.686 | 0.730 | 0.693 | 0.761 | 0.774 | 0.754 | 0.725 | 0.850 | 0.922 |
| February | 0.827 | 0.771 | 0.676 | 0.762 | 0.714 | 0.734 | 0.763 | 0.737 | 0.737 | 0.882 | 0.882 |
| March | 0.844 | 0.755 | 0.661 | 0.782 | 0.741 | 0.728 | 0.746 | 0.773 | 0.731 | 0.943 | 0.895 |
| April | 0.827 | 0.750 | 0.634 | 0.759 | 0.743 | 0.710 | 0.753 | 0.783 | 0.727 | 0.923 | 0.887 |
| May | 0.791 | 0.732 | 0.642 | 0.744 | 0.774 | 0.675 | 0.755 | 0.764 | 0.723 | 0.904 | 0.882 |
| June | 0.778 | 0.744 | 0.643 | 0.717 | 0.819 | 0.702 | 0.805 | 0.767 | 0.735 | 0.894 | 0.897 |
| July | 0.796 | 0.740 | 0.636 | 0.711 | 0.811 | 0.699 | 0.804 | 0.767 | 0.736 | 0.905 | 0.901 |
| August | 0.784 | 0.731 | 0.658 | 0.712 | 0.763 | 0.700 | 0.816 | 0.754 | 0.748 | 0.915 | 0.895 |
| September | 0.780 | 0.734 | 0.698 | 0.695 | 0.787 | 0.688 | 0.797 | 0.755 | 0.759 | 0.889 | 0.897 |
| October | 0.788 | 0.705 | 0.729 | 0.688 | 0.735 | 0.733 | 0.777 | 0.737 | 0.787 | 0.891 | 0.906 |
| November | 0.786 | 0.694 | 0.773 | 0.676 | 0.720 | 0.707 | 0.772 | 0.726 | 0.803 | 0.912 | 0.920 |
| December | 0.759 | 0.678 | 0.758 | 0.664 | 0.764 | 0.750 | 0.770 | 0.736 | 0.820 | 0.914 | 0.942 |
| Annual Average | 0.800 | 0.733 | 0.683 | 0.720 | 0.755 | 0.716 | 0.778 | 0.754 | 0.753 | 0.902 | 0.902 |
| Biennial Average | | 0.767 | | 0.701 | | 0.735 | | 0.766 | | 0.827 | |
| | | 2006/2007 | | 2008/2009 | | 2010/2011 | | 2012/2013 | | 2014/2015 | |
| Budget 2006/2007 approved at 0.815 €/US\$ | | | Budget 2010/2011 approved at 0.660 €/US\$ | | | Budget 2014/2015 approved at 0.758 €/US\$ | | | | | |
| Budget 2008/2009 approved at 0.815 €/US\$ | | | Budget 2012/2013 approved at 0.675 €/US\$ | | | Budget 2016/2017 approved at 0.729 €/US\$ | | | | | |

| Information Table C | | | |
|--|--|---|---|
| IARC PROJECT TREE STRUCTURE AND ASSOCIATED PROJECTS | | | |
| LEVEL 1 OBJECTIVE: Reduce the burden of cancer worldwide through the conduct of research | | | |
| <i>Level 2/3 Objectives</i> | <i>Level 4 Objectives</i> | <i>Project Number</i> | <i>Project Title</i> |
| 1 Describe the occurrence of cancer | | | |
| 1.1 Improve and expand reporting of descriptive cancer statistics | 1.1.1 Expand the descriptive analyses of cancer incidence, mortality, prevalence and survival regionally and worldwide | PB.1819.CSU.03 | Descriptive epidemiology of cancer |
| | 1.1.2 Improve the validity, range, timeliness and dissemination of appropriate cancer indicators available at the national, regional and global level | PB.1819.CSU.01 | Global cancer indicators: development and dissemination |
| 1.2 Support improved coverage and quality of cancer registration, particularly in low and middle-income countries (LMIC) | 1.2.1 Improve the availability, quality and dissemination of registry data, via IARC Regional Hubs and promote the role of population-based cancer registries in cancer control planning | PB.1819.CSU.02 | Cancer registry support and development |
| 1.3 Improve tumour classification to inform cancer registration, research and treatment | 1.3.1 Publish WHO Classification of Tumours Series | PB.1819.IMO.03 | WHO classification of tumours series |
| 2 Understand the causes of cancer | | | |
| 2.1 Identify the risk factors for human cancer through the conduct of epidemiological studies | 2.1.1 Advance understanding of the role of infectious agents | PB.1819.ICB.02 | Determine the role of infectious agents in different human cancers |
| | | PB.1819.ICE.02 | Spectrum, natural history, and prevention of infection-associated cancers |
| | 2.1.2 Advance understanding of the role of environmental, occupational and iatrogenic factors | PB.1819.ENV.01 | To study carcinogenic effects of exposure to protracted low doses of ionising radiation |
| | | PB.1819.ENV.02 | To study exposure to non-ionising radiation (electromagnetic fields) |
| | | PB.1819.ENV.03 | To study cancers with suspected environmental, occupational or lifestyle-related causes |
| | | PB.1819.ENV.04 | To study unique environmental, lifestyle and occupational exposures |
| | 2.1.3 Advance understanding of the role of dietary, metabolic and lifestyle factors | PB.1819.BMA.01 | Dietary and metabolic biomarkers associated with cancer and intermediate end-points |
| | | PB.1819.NEP.01 | Molecular epidemiologic studies of nutrition and metabolism and cancer |
| | | PB.1819.NMB.02 | Dietary and lifestyle exposures associated with cancer and other non-communicable diseases |
| | 2.1.4 Advance understanding of the role of genetic factors in influencing risk, and their interaction with non-genetic factors | PB.1819.GCS.01 | Identify genes involved in cancer development |
| | | PB.1819.GEP.01 | Genetic epidemiology of tobacco and alcohol related cancer |
| | | PB.1819.GEP.02 | Kidney cancer molecular epidemiology |
| | 2.2 Elucidate mechanisms of carcinogenesis through the conduct of laboratory studies | 2.2.1 Advance understanding of biological and cellular pathways | PB.1819.EGE.01 |
| PB.1819.ICB.01 | | | Biological properties of infectious agents in in vitro and in vivo experimental models |
| PB.1819.MMB.01 | | | Somatic alterations and mechanisms of carcinogenesis associated with exposure to environmental risk factors |
| 2.2.2 Apply biomarkers to studies of cancer causes and molecular genetic classification of tumours | | PB.1819.EGE.02 | Epigenetics-based biomarkers in exposomics |
| | | PB.1819.MMB.02 | Molecular alterations as biomarkers of exposure, cancer risk and detection |
| 2.3 Provide expert evaluations of the available evidence-base to identify human carcinogens | 2.3.1 Publish IARC Monographs and associated outputs on strategically related topics | PB.1819.IMO.01 | IARC Monographs on the Evaluation of Carcinogenic Risks to Humans |
| 3 Evaluate and implement cancer prevention and control strategies | | | |
| 3.1 Enhance understanding of interventions for cancer prevention and control | 3.1.1 Analyse the efficacy of primary cancer prevention strategies | PB.1819.GHI.01 | Gambia Hepatitis Intervention Study (GHIS) |
| | | PB.1819.ICE.01 | Implementation and monitoring of HPV vaccination and HPV-based screening in low and middle-income countries |
| | | PB.1819.PRI.03 | Epidemiology and prevention of gastric cancer |
| | 3.1.2 Analyse the efficacy of secondary cancer prevention strategies | PB.1819.PRI.02 | Cervical cancer screening strategies for low and middle income countries |
| | 3.1.3 Enhance understanding of the factors affecting cancer prognosis | PB.1819.ENV.05 | To study lifestyle and environmental determinants of cancer risks, prognosis and cancer outcomes |
| | | PB.1819.SCR.03 | Improving the quality of breast cancer screening, early diagnosis and treatment services in LMICs |
| 3.2 Enhance the implementation of cancer prevention and control programmes | 3.2.1 Identify factors influencing the effective implementation of primary and secondary prevention programmes | PB.1819.ENV.06 | Expansion and evaluation of Cancer Prevention Recommendations |
| | | PB.1819.PRI.01 | Implementation studies of HPV vaccination |
| | | PB.1819.SCR.01 | Evaluation of cervical cancer control measures in developing countries |
| | | PB.1819.SCR.02 | Evaluation of colorectal and oral cancer screening |
| | | PB.1819.SCR.04 | Cancer Screening Initiatives & Their Impact in 5 Continents |

| Information Table C | | | |
|---|---|--|--|
| IARC PROJECT TREE STRUCTURE AND ASSOCIATED PROJECTS | | | |
| LEVEL 1 OBJECTIVE: Reduce the burden of cancer worldwide through the conduct of research | | | |
| <i>Level 2/3 Objectives</i> | <i>Level 4 Objectives</i> | <i>Project Number</i> | <i>Project Title</i> |
| 3.3 Provide expert evaluations of the available evidence-base in order to recommend prevention strategies | 3.3.1 Publish IARC Handbooks on Cancer Prevention | PB.1819.IMO.02 | IARC Handbooks of Cancer Prevention |
| 4 Increase the capacity for cancer research | | | |
| 4.1 Increase human resources for cancer research | 4.1.1 Award fellowships and provide training through participation in collaborative research projects | PB.1819.ETR.01 | IARC Research Training and Fellowship Programme |
| | 4.1.2 Deliver training courses, basic and advanced, in the areas of core competencies of the Agency | PB.1819.ETR.02 | IARC Courses |
| 4.2 Develop new methodologies for cancer research | 4.2.1 Improve and implement epidemiological, statistical and bioinformatics methods | PB.1819.ENV.07 | Contribute to advanced biostatistical analyses and developing biostatistical methods |
| | | PB.1819.ICE.03 | Improving statistical methods and models to estimate infection-associated cancers |
| | | PB.1819.NMB.01 | Integration of lifestyle and –omics-based exposures in aetiological models for cancer research |
| | 4.2.2 Improve and implement laboratory methods | PB.1819.BMA.02 | Metabolomics-based development of biomarkers of foods, food constituents, food contaminants and metabolism |
| | | PB.1819.EGE.03 | Epigenomic profiling applicable to molecular epidemiology |
| | | PB.1819.GCS.02 | Non-invasive biomarkers for early detection of cancer |
| | | PB.1819.MMB.03 | Experimental methodologies and bioinformatic resources for molecular cancer research |
| | | PB.1819.NEP.02 | Novel tools and platforms for nutrition assessment in cancer epidemiology |
| 4.3 Provide the resources and infrastructure to support and enhance research | 4.3.1 Develop and maintain research platforms | PB.1819.GEP.03 | Coordination of large cohort studies as research platforms |
| | | PB.1819.LSB.01 | Management of IARC biobank and pre-analytical processing services |
| | | PB.1819.LSB.03 | Capacity building and biobank infrastructure support for Low and Middle Income Countries (LMIC) |
| | 4.3.2 Develop and maintain laboratory and computing services | PB.1819.GCS.03 | Genetics Platform |
| | | PB.1819.LSB.02 | Laboratory Services support |
| | | PB.1819.LSB.04 | Histology laboratory |
| | | PB.1819.MMB.04 | The IARC TP53 Database |
| | 4.3.3 Respond to emerging research opportunities and demands by supporting new or ongoing initiatives | PB.1819.SSR.03 | Laboratory and computing services |
| | | PB.1819.DIR.03 | Strategic Research Investment |
| 5 Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research | | | |
| 5.1 Define the vision and implement the scientific strategy of the Agency, providing the framework for the fulfilment of its objectives | 5.1.1 Define the vision and implement the scientific strategy of the Agency, providing the framework for the fulfilment of its objectives | PB.1819.DIR.01 | Direction and Leadership |
| 5.2 Oversee the strategic direction of the Agency and the implementation of its programme | 5.2.1 Oversee the strategic direction of the Agency and the implementation of its programme | PB.1819.SSR.05 | Support to Governing and Scientific Council meetings and interactions with Participating States |
| 5.3 Create and maintain key strategic partnerships with national, regional and international organizations | 5.3.1 Create and maintain key strategic partnerships with national, regional and international organizations | PB.1819.DIR.02 | Strategic Partnerships |
| 5.4 Effectively communicate and disseminate the work of the Agency | 5.4.1 Effectively communicate and disseminate the work of the Agency | PB.1819.COM.01 | Information Services and Dissemination |
| | | PB.1819.COM.02 | Editing, Layout, and Translation |
| | | PB.1819.COM.03 | Web Services |
| | | PB.1819.COM.04 | Media Relations and Multimedia |
| 6 Enable and support the efficient conduct and coordination of research | | | |
| 6.1 Ensure the Agency is directed and managed according to highest sector standards | 6.1.1 Provide sound management of human and infrastructure resources | PB.1819.SSR.01 | Sound management of human and infrastructure resources |
| | 6.1.2 Ensure the funding requirements for the Agency's activities are met and available resources are disbursed in line with the strategy | PB.1819.SSR.06 | Nouveau Centre |
| 6.2 Invest strategically towards increasing IARC's capacity | | 6.2.1 Ensure a work culture that encourages exploring new approaches and opportunities | PB.1819.SSR.02 |
| | PB.1819.SSR.04 | | Work culture to encourage new approaches and opportunities |

| Information Table D | | | | | | | | | | | | | | |
|--|---|------------|----------------------|-------------------------------------|------------|----------------------|-------------------------------------|------------|----------------------|-------------------------------------|------------|----------------------|--|--|
| GROUP CLASSIFICATION OF COUNTRIES AND ASSIGNING UNITS FOR ASSESSED CONTRIBUTIONS | | | | | | | | | | | | | | |
| From 2012 to 2019 | | | | | | | | | | | | | | |
| GROUP CLASSIFICATION OF COUNTRIES AS PER RESOLUTION GC/15/R9 | | | | | | | | | | | | | | |
| WHO's % Contribution | | | IARC Group | | | IARC Scale (# units) | | | | | | | | |
| 8% and above | | | 1 | | | 8 | | | | | | | | |
| 4% and above; below 8% | | | 2 | | | 4 | | | | | | | | |
| 2% and above; below 4% | | | 3 | | | 2 | | | | | | | | |
| 0.5% and above; below 2% | | | 4 | | | 1 | | | | | | | | |
| less than 0.5% | | | 5 | | | 0 | | | | | | | | |
| GROUP AND UNIT ASSIGNED TO EACH PARTICIPATING STATE | | | | | | | | | | | | | | |
| Participating State | REVISED SCALE for 2018-2019 PROPOSED BUDGET | | | SCALE for 2016-2017 APPROVED BUDGET | | | SCALE for 2014-2015 APPROVED BUDGET | | | SCALE for 2012-2013 APPROVED BUDGET | | | | |
| | WHO's % Contribution (WHA69.14) | IARC Group | IARC Scale (# units) | WHO's % Contribution (WHA68.12) | IARC Group | IARC Scale (# units) | WHO's % Contribution | IARC Group | IARC Scale (# units) | WHO's % Contribution | IARC Group | IARC Scale (# units) | | |
| Australia | 2.3371 | 3 | 2 | 2.0741 | 3 | 2 | 2.0741 | 3 | 2 | 1.9331 | 4 | 1 | | |
| Austria | 0.7201 | 4 | 1 | 0.7981 | 4 | 1 | 0.7981 | 4 | 1 | 0.8511 | 4 | 1 | | |
| Belgium | 0.8851 | 4 | 1 | 0.9981 | 4 | 1 | 0.9981 | 4 | 1 | 1.0751 | 4 | 1 | | |
| Brazil | 3.8232 | 3 | 2 | 2.9342 | 3 | 2 | 2.9342 | 3 | 2 | 1.6111 | 4 | 1 | | |
| Canada | 2.9211 | 3 | 2 | 2.9842 | 3 | 2 | 2.9842 | 3 | 2 | 3.2072 | 3 | 2 | | |
| Denmark | 0.5840 | 4 | 1 | 0.6750 | 4 | 1 | 0.6750 | 4 | 1 | 0.7361 | 4 | 1 | | |
| Finland | 0.4560 | 5 | 0 | 0.5190 | 4 | 1 | 0.5190 | 4 | 1 | 0.5660 | 4 | 1 | | |
| France | 4.8592 | 2 | 4 | 5.5935 | 2 | 4 | 5.5935 | 2 | 4 | 6.1234 | 2 | 4 | | |
| Germany | 6.3892 | 2 | 4 | 7.1416 | 2 | 4 | 7.1416 | 2 | 4 | 8.0186 | 1 | 8 | | |
| India | 0.7370 | 4 | 1 | 0.6660 | 4 | 1 | 0.6660 | 4 | 1 | 0.5340 | 4 | 1 | | |
| Ireland | 0.3350 | 5 | 0 | 0.4180 | 5 | 0 | 0.4180 | 5 | 0 | 0.4980 | 5 | 0 | | |
| Italy | 3.7482 | 3 | 2 | 4.4483 | 2 | 4 | 4.4483 | 2 | 4 | 4.9994 | 2 | 4 | | |
| Japan | 9.6802 | 1 | 8 | 10.8338 | 1 | 8 | 10.8338 | 1 | 8 | 12.5309 | 1 | 8 | | |
| Morocco | 0.0540 | 5 | 0 | 0.0620 | 5 | 0 | 0.0620 | 5 | 0 | 0.0580 | 5 | 0 | | |
| Netherlands | 1.4821 | 4 | 1 | 1.6541 | 4 | 1 | 1.6541 | 4 | 1 | 1.8551 | 4 | 1 | | |
| Norway | 0.8491 | 4 | 1 | 0.8511 | 4 | 1 | 0.8511 | 4 | 1 | 0.8711 | 4 | 1 | | |
| Qatar | 0.2690 | 5 | 0 | 0.2090 | 5 | 0 | 0.2090 | 5 | 0 | 0.1350 | 5 | 0 | | |
| Republic of Korea | 2.0391 | 3 | 2 | 1.9941 | 4 | 1 | 1.9941 | 4 | 1 | 2.2602 | 3 | 2 | | |
| Russian Federation | 3.0882 | 3 | 2 | 2.4382 | 3 | 2 | 2.4382 | 3 | 2 | 1.6021 | 4 | 1 | | |
| Spain | 2.4431 | 3 | 2 | 2.9732 | 3 | 2 | 2.9732 | 3 | 2 | 3.1772 | 3 | 2 | | |
| Sweden | 0.9561 | 4 | 1 | 0.9601 | 4 | 1 | 0.9601 | 4 | 1 | 1.0641 | 4 | 1 | | |
| Switzerland | 1.1401 | 4 | 1 | 1.0471 | 4 | 1 | 1.0471 | 4 | 1 | 1.1301 | 4 | 1 | | |
| Turkey | 1.0181 | 4 | 1 | 1.3281 | 4 | 1 | 1.3281 | 4 | 1 | 0.6170 | 4 | 1 | | |
| United Kingdom | 4.4632 | 2 | 4 | 5.1794 | 2 | 4 | 5.1794 | 2 | 4 | 6.6045 | 2 | 4 | | |
| United States of America | 22.0000 | 1 | 8 | 22.0000 | 1 | 8 | 22.0000 | 1 | 8 | 22.0000 | 1 | 8 | | |

| Information Table E | | | | | | | | | | | |
|--|---------------------------|--|-------------------|-------------|------------------|--|-------------------|---------------------|----------------------------|--|---|
| COMPARISON OF ASSESSMENTS ON PARTICIPATING STATES BASED ON CURRENT AND REVISED SCALES | | | | | | | | | | | |
| (expressed in euros) | | | | | | | | | | | |
| PARTICIPATING STATE | Approved Budget 2016-2017 | Proposed Budget 2018-2019 distributed based on the same scale used in 2016-2017 Budget | | | | Proposed Budget 2018-2019 distributed based on the revised scale | | | | <i>Incremental Increase/(decrease) from current to revised scale</i> | <i>Change in country group classification</i> |
| | | Units | 2018-2019 | % increase | Increase Amount | Units | 2018-2019 | % increase/decrease | Amount Increase/(decrease) | | |
| Australia | 1,737,461 | 2 | 1,736,005 | -0.08 | -1,456 | 2 | 1,755,604 | 1.04 | 18,143 | 19,599 | |
| Austria | 1,494,554 | 1 | 1,486,098 | -0.57 | -8,456 | 1 | 1,495,898 | 0.09 | 1,344 | 9,800 | |
| Belgium | 1,494,554 | 1 | 1,486,098 | -0.57 | -8,456 | 1 | 1,495,898 | 0.09 | 1,344 | 9,800 | |
| Brazil | 1,737,461 | 2 | 1,736,005 | -0.08 | -1,456 | 2 | 1,755,604 | 1.04 | 18,143 | 19,599 | |
| Canada | 1,737,461 | 2 | 1,736,005 | -0.08 | -1,456 | 2 | 1,755,604 | 1.04 | 18,143 | 19,599 | |
| Denmark | 1,494,554 | 1 | 1,486,098 | -0.57 | -8,456 | 1 | 1,495,898 | 0.09 | 1,344 | 9,800 | |
| Finland | 1,494,554 | 1 | 1,486,098 | -0.57 | -8,456 | 0 | 1,236,194 | -17.29 | (258,360) | (249,904) | change from group 4 to 5 |
| France | 2,223,275 | 4 | 2,235,812 | 0.56 | 12,537 | 4 | 2,275,015 | 2.33 | 51,740 | 39,203 | |
| Germany | 2,223,275 | 4 | 2,235,812 | 0.56 | 12,537 | 4 | 2,275,015 | 2.33 | 51,740 | 39,203 | |
| India | 1,494,554 | 1 | 1,486,098 | -0.57 | -8,456 | 1 | 1,495,898 | 0.09 | 1,344 | 9,800 | |
| Ireland | 1,251,647 | 0 | 1,236,194 | -1.23 | -15,453 | 0 | 1,236,194 | -1.23 | (15,453) | 0 | |
| Italy | 2,223,275 | 4 | 2,235,812 | 0.56 | 12,537 | 2 | 1,755,604 | -21.04 | (467,671) | (480,208) | change from group 2 to 3 |
| Japan | 3,194,903 | 8 | 3,235,430 | 1.27 | 40,527 | 8 | 3,313,831 | 3.72 | 118,928 | 78,401 | |
| Morocco | 0 | 0 | 1,236,194 | | 1,236,194 | 0 | 1,236,194 | | 1,236,194 | 0 | |
| Netherlands | 1,494,554 | 1 | 1,486,098 | -0.57 | -8,456 | 1 | 1,495,898 | 0.09 | 1,344 | 9,800 | |
| Norway | 1,494,554 | 1 | 1,486,098 | -0.57 | -8,456 | 1 | 1,495,898 | 0.09 | 1,344 | 9,800 | |
| Qatar | 1,251,647 | 0 | 1,236,194 | -1.23 | -15,453 | 0 | 1,236,194 | -1.23 | (15,453) | 0 | |
| Republic of Korea | 1,494,554 | 1 | 1,486,098 | -0.57 | -8,456 | 2 | 1,755,604 | 17.47 | 261,050 | 269,506 | change from group 4 to 3 |
| Russian Federation | 1,737,461 | 2 | 1,736,005 | -0.08 | -1,456 | 2 | 1,755,604 | 1.04 | 18,143 | 19,599 | |
| Spain | 1,737,461 | 2 | 1,736,005 | -0.08 | -1,456 | 2 | 1,755,604 | 1.04 | 18,143 | 19,599 | |
| Sweden | 1,494,554 | 1 | 1,486,098 | -0.57 | -8,456 | 1 | 1,495,898 | 0.09 | 1,344 | 9,800 | |
| Switzerland | 1,494,554 | 1 | 1,486,098 | -0.57 | -8,456 | 1 | 1,495,898 | 0.09 | 1,344 | 9,800 | |
| Turkey | 1,494,554 | 1 | 1,486,098 | -0.57 | -8,456 | 1 | 1,495,898 | 0.09 | 1,344 | 9,800 | |
| United Kingdom | 2,223,275 | 4 | 2,235,812 | 0.56 | 12,537 | 4 | 2,275,015 | 2.33 | 51,740 | 39,203 | |
| United States of America | 3,194,903 | 8 | 3,235,430 | 1.27 | 40,527 | 8 | 3,313,831 | 3.72 | 118,928 | 78,401 | |
| TOTAL | 42,913,599 | 53 | 44,149,793 | 2.88 | 1,236,194 | 51 | 44,149,793 | 2.88 | 1,236,194 | 0 | |

| Information Table F COMPARISON OF PROPOSED REGULAR BUDGET 2018-2019 WITH A APPROVED REGULAR BUDGET 2016-2017 BY LEVEL 2/3 OBJECTIVES (expressed in euros) | | | | | | | | |
|---|---|-----------------------------|----------------------------------|--------------------|------------------------------------|---------------------|----------|----------|
| Level 2 | Level 2 Objectives | REGULAR BUDGETARY RESOURCES | | | Increase/(Decrease) from 2016-2017 | | | % Change |
| | | Staff Budget 2018-2019 | Non-staff Budget 2018-2019 | Total 2018-2019 | Staff Budget | Non-staff Budget | Total | |
| Level 3 | Level 3 Objectives | | | | | | | |
| 1 | Describe the occurrence of cancer | | | | | | | |
| 1.1 | Improve and expand reporting of descriptive cancer statistics | 1,891,815 | 180,000 | 2,071,815 | 111,938 | 1,000 | 112,938 | 5.77 |
| 1.2 | Support improved coverage and quality of cancer registration, particularly in low and middle-income countries (LMIC) | 677,061 | 190,000 | 867,061 | 18,344 | 0 | 18,344 | 2.16 |
| 1.3 | Improve tumour classification to inform cancer registration, research and treatment | 462,517 | 106,000 | 568,517 | 176,633 | 29,000 | 205,633 | 56.67 |
| | | 3,031,393 | 476,000 | 3,507,393 | 306,915 | 30,000 | 336,915 | 10.63 |
| 2 | Understand the causes of cancer | | | | | | | |
| 2.1 | Identify the risk factors for human cancer through the conduct of epidemiological studies | 6,182,167 | 872,800 | 7,054,967 | 29,755 | -31,200 | -1,445 | -0.02 |
| 2.2 | Elucidate mechanisms of carcinogenesis through the conduct of laboratory studies | 2,406,002 | 419,400 | 2,825,402 | -531,913 | -218,600 | -750,513 | -20.99 |
| 2.3 | Provide expert evaluations of the available evidence-base to identify human carcinogens | 1,598,737 | 240,000 | 1,838,737 | 62,188 | 83,200 | 145,388 | 8.59 |
| | | 10,186,906 | 1,532,200 | 11,719,106 | -439,970 | -166,600 | -606,570 | -4.92 |
| 3 | Evaluate and implement cancer prevention and control strategies | | | | | | | |
| 3.1 | Enhance understanding of interventions for cancer prevention and control | 2,126,331 | 455,000 | 2,581,331 | 48,839 | -106,508 | -57,669 | -2.19 |
| 3.2 | Enhance the implementation of cancer prevention and control programmes | 1,077,232 | 123,000 | 1,200,232 | -175,601 | 32,000 | -143,601 | -10.69 |
| 3.3 | Provide expert evaluations of the available evidence-base in order to recommend prevention strategies | 476,225 | 60,000 | 536,225 | 77,994 | 20,800 | 98,794 | 22.59 |
| | | 3,679,788 | 638,000 | 4,317,788 | -48,768 | -53,708 | -102,476 | -2.32 |
| 4 | Increase the capacity for cancer research | | | | | | | |
| 4.1 | Increase human resources for cancer research | 724,571 | 693,000 | 1,417,571 | 22,378 | -237,000 | -214,622 | -13.15 |
| 4.2 | Develop new methodologies for cancer research | 3,194,747 | 398,200 | 3,592,947 | 667,978 | 44,200 | 712,178 | 24.72 |
| 4.3 | Provide the resources and infrastructure to support and enhance research | 3,117,425 | 2,822,594 | 5,940,019 | 317,296 | -145,662 | 171,634 | 2.98 |
| | | 7,036,743 | 3,913,794 | 10,950,537 | 1,007,652 | -338,462 | 669,190 | 6.51 |
| 5 | Provide strategic leadership and enhance the impact of the Agency's contribution to global cancer research | | | | | | | |
| 5.1 | Define the vision and implement the scientific strategy of the Agency, providing the framework for the fulfilment of its objectives | 818,283 | 540,000 | 1,358,283 | 83,992 | -10,000 | 73,992 | 5.76 |
| 5.2 | Oversee the strategic direction of the Agency and the implementation of its programme | 179,701 | 219,000 | 398,701 | 6,510 | 0 | 6,510 | 1.66 |
| 5.3 | Create and maintain key strategic partnerships with national, regional and international organizations | 467,675 | 150,000 | 617,675 | 192,786 | 0 | 192,786 | 45.37 |
| 5.4 | Effectively communicate and disseminate the work of the Agency | 1,883,289 | 542,000 | 2,425,289 | 68,407 | 0 | 68,407 | 2.90 |
| | | 3,348,948 | 1,451,000 | 4,799,948 | 351,695 | -10,000 | 341,695 | 7.66 |
| 6 | Enable and support the efficient conduct and coordination of research | | | | | | | |
| 6.1 | Ensure the Agency is directed and managed according to highest sector standards | 6,605,582 | 1,790,516 | 8,396,098 | 200,687 | -53,010 | 147,677 | 1.79 |
| 6.2 | Invest strategically towards increasing IARC's capacity | 303,923 | 155,000 | 458,923 | -30,237 | -20,000 | -50,237 | -9.87 |
| | | 6,909,505 | 1,945,516 | 8,855,021 | 170,450 | -73,010 | 97,440 | 1.11 |
| | TOTAL | 34,193,283 | 9,956,510 | 44,149,793 | 1,347,974 | -611,780 | 736,194 | 1.70 |